REFERENCES
1. Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167-92.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
4. Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025;18:42.
5. eir HK, Carreira H, et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-1010.
6. Wei H, Li W, Zeng L, et al. OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway. Mol Cancer. 2024;23:124.
8. Kohoutova D, Banks M, Bures J. Advances in the aetiology & endoscopic detection and management of early gastric cancer. Cancers. 2021;13:6242.
9. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20:13842-62.
10. Levy I, Gralnek IM. Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy. Best Pract Res Clin Gastroenterol. 2016;30:705-18.
11. Huang RJ, Park S, Shen J, Longacre T, Ji H, Hwang JH. Pepsinogens and gastrin demonstrate low discrimination for gastric precancerous lesions in a multi-ethnic United States cohort. Clin Gastroenterol Hepatol. 2022;20:950-2.e3.
12. So JBY, Kapoor R, Zhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021;70:829-37.
13. Otsu H, Nambara S, Hu Q, et al. Identification of serum microRNAs as potential diagnostic biomarkers for detecting precancerous lesions of gastric cancer. Ann Gastroenterol Surg. 2023;7:63-70.
14. Liu ZC, Wu WH, Huang S, et al. Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study. Theranostics. 2022;12:4671-83.
15. Gong Y, Lou Y, Han X, et al. Serum proteomic profiling of precancerous gastric lesions and early gastric cancer reveals signatures associated with systemic inflammatory response and metaplastic differentiation. Front Mol Biosci. 2024;11:1252058.
16. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.
17. Alix-Panabières C, Pantel K. Liquid Biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858-73.
18. Li J, Zhao W, Yang J, et al. Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population. Sci Rep. 2024;14:25309.
19. Zhu Q, He P, Zheng C, et al. Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion. J Cancer Res Clin Oncol. 2023;149:8369-78.
20. Chen J, Liu Z, Gao G, et al. Efficacy of circulating microRNA-130b and blood routine parameters in the early diagnosis of gastric cancer. Oncol Lett. 2021;22:725.
21. Jin Y, Chen K, Wang Z, et al. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016;16:753.
22. Kolesar J, Peh S, Thomas L, et al. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Mol Cancer. 2022;21:61.
23. Song P, Wu LR, Yan YH, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022;6:232-45.
24. Batool SM, Yekula A, Khanna P, et al. The liquid biopsy consortium: challenges and opportunities for early cancer detection and monitoring. Cell Rep Med. 2023;4:101198.
25. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024;42:1301-12.e7.
26. Ciani Y, Nardella C, Demichelis F. Casting a wider net: the clinical potential of EV transcriptomics in multi-analyte liquid biopsy. Cancer Cell. 2024;42:1160-2.
27. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213-28.
28. Maacha S, Bhat AA, Jimenez L, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer. 2019;18:55.
29. Niu L, Zhu Y, Wan M, et al. Extracellular DNA as potential contributors to pathological calcification. Interdiscip Med. 2024;2:e20230061.
30. Iannotta D, A A, Kijas AW, Rowan AE, Wolfram J. Entry and exit of extracellular vesicles to and from the blood circulation. Nat Nanotechnol. 2024;19:13-20.
31. Nieuwland R, Siljander PR. A beginner’s guide to study extracellular vesicles in human blood plasma and serum. J Extracell Vesicles. 2024;13:e12400.
32. Zhu Z, Hu E, Shen H, Tan J, Zeng S. The functional and clinical roles of liquid biopsy in patient-derived models. J Hematol Oncol. 2023;16:36.
33. Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017;28:741-7.
34. Choi J, Cho HY, Jeon J, et al. Detection of circulating KRAS mutant DNA in extracellular vesicles using droplet digital PCR in patients with colon cancer. Front Oncol. 2022;12:1067210.
35. Greenberg MVC, Bourc’his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20:590-607.
36. Oliva M, Demanelis K, Lu Y, et al. DNA methylation QTL mapping across diverse human tissues provides molecular links between genetic variation and complex traits. Nat Genet. 2023;55:112-22.
37. Fu Y, Jiang J, Wu Y, et al. Genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA as noninvasive diagnostic markers for gastric cancer. Gastric Cancer. 2024;27:735-46.
38. Tian X, Sun B, Chen C, et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. Cell Res. 2018;28:597-600.
39. Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-205.
40. West-Szymanski DC, Zhang Z, Cui XL, et al. 5-hydroxymethylated biomarkers in cell-free DNA predict occult colorectal cancer up to 36 months before diagnosis in the prostate, lung, colorectal, and ovarian cancer screening trial. JCO Precis Oncol. 2024;8:e2400277.
41. Luo Z, Li W, Zheng W, et al. Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: a 12-year median follow-up study. Clin Transl Med. 2024;14:e70114.
42. Chinese Society of Gastroenterology, Cancer Collaboration Group of Chinese Society of Gastroenterology, Chinese Medical Association. Guidelines for diagnosis and treatment of chronic gastritis in China (2022, Shanghai). J Dig Dis. 2023;24:150-80.
43. Chu JL, Bi SH, He Y, et al. 5-hydroxymethylcytosine profiles in plasma cell-free DNA reflect molecular characteristics of diabetic kidney disease. Front Endocrinol. 2022;13:910907.
44. Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29:68-72.
46. Etherington GJ, Ramirez-Gonzalez RH, MacLean D. Bio-samtools 2: a package for analysis and visualization of sequence and alignment data with SAMtools in ruby. Bioinformatics. 2015;31:2565-7.
47. Navarro Gonzalez J, Zweig AS, Speir ML, et al. The UCSC genome browser database: 2021 update. Nucleic Acids Res. 2021;49:D1046-57.
48. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841-2.
49. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
50. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
51. Kumar L, E Futschik M. Mfuzz: a software package for soft clustering of microarray data. Bioinformation. 2007;2:5-7.
52. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.
53. Lu D, Wu X, Wu W, et al. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer. Cell Death Dis. 2023;14:843.
54. Liu S, Ji H, Zhang T, et al. Modified Zuojin pill alleviates gastric precancerous lesions by inhibiting glycolysis through the HIF-1α pathway. Phytomedicine. 2025;136:156255.
55. Cai Q, Shi P, Yuan Y, et al. Inflammation-associated senescence promotes helicobacter pylori-induced atrophic gastritis. Cell Mol Gastroenterol Hepatol. 2021;11:857-80.
56. Milito C, Pulvirenti F, Garzi G, et al. Decline of gastric cancer mortality in common variable immunodeficiency in the years 2018-2022. Front Immunol. 2023;14:1231242.
57. Murata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26:4617-26.
58. Wang YM, Luo ZW, Shu YL, et al. Effects of Helicobacter pylori and Moluodan on the Wnt/β-catenin signaling pathway in mice with precancerous gastric cancer lesions. World J Gastrointest Oncol. 2024;16:979-90.
59. Wang Y, Chu F, Lin J, et al. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification. J Ethnopharmacol. 2021;279:114399.
60. Yi Z, Jia Q, Lin Y, et al. Mechanism of Elian granules in the treatment of precancerous lesions of gastric cancer in rats through the MAPK signalling pathway based on network pharmacology. Pharm Biol. 2022;60:87-95.
61. Luo Z, Li W, Zheng W, et al. Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: a 12-year median follow-up study. Clin Transl Med. 2024;14:e70114.
62. He S, Zhang Z, Song G, et al. Can patients with mild non-neoplastic lesions diagnosed at baseline screening be safely exempt from surveillance: evidence from multicenter community-based cohorts. Sci China Life Sci. 2025;68:263-71.
63. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635-48.
64. Young E, Philpott H, Singh R. Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: current evidence and what the future may hold. World J Gastroenterol. 2021;27:5126-51.
65. Yang Y, Guan S, Ou Z, Li W, Yan L, Situ B. Advances in AI-based cancer cytopathology. Interd Med. 2023;1:e20230013.
66. Guo X, Peng Y, Song Q, et al. A liquid biopsy signature for the early detection of gastric cancer in patients. Gastroenterology. 2023;165:402-13.e13.
67. Ge X, Zhang X, Ma Y, Chen S, Chen Z, Li M. Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening. J Clin Lab Anal. 2021;35:e23568.
68. Lopes C, Almeida TC, Macedo-Silva C, et al. MIR124-3 and NKX6-1 hypermethylation profiles accurately predict metachronous gastric lesions in a Caucasian population. Clin Epigenetics. 2024;16:113.
69. Jian J, Feng Y, Wang R, et al. METTL3-regulated lncRNA SNHG7 drives MNNG-induced epithelial-mesenchymal transition in gastric precancerous lesions. Toxics. 2024;12:573.
70. Zhang L, Wang N, Chen M, et al. HDAC6/FOXP3/HNF4α axis promotes bile acids induced gastric intestinal metaplasia. Am J Cancer Res. 2022;12:1409-22.
71. Zhou X, Kurywchak P, Wolf-Dennen K, et al. Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. Mol Ther Methods Clin Dev. 2021;22:360-76.
72. Cho SM, Shin S, Kim Y, et al. A novel approach for tuberculosis diagnosis using exosomal DNA and droplet digital PCR. Clin Microbiol Infect. 2020;26:942.e1-5.
73. Sedej I, Štalekar M, Tušek Žnidarič M, et al. Extracellular vesicle-bound DNA in urine is indicative of kidney allograft injury. J Extracell Vesicles. 2022;11:e12268.
74. Picca A, Guerra F, Calvani R, et al. Mitochondrial-derived vesicles as candidate biomarkers in parkinson’s disease: rationale, design and methods of the EXosomes in PArkiNson disease (EXPAND) study. Int J Mol Sci. 2019;20:2373.
75. Elzanowska J, Semira C, Costa-Silva B. DNA in extracellular vesicles: biological and clinical aspects. Mol Oncol. 2021;15:1701-14.
76. Fenech M, Kirsch-Volders M, Natarajan AT, et al. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis. 2011;26:125-32.
77. Lin B, Jiao Z, Dong S, et al. Whole-genome methylation profiling of extracellular vesicle DNA in gastric cancer identifies intercellular communication features. Nat Commun. 2025;16:8084.
78. Bussiere FI, Chaturvedi R, Asim M, et al. Low multiplicity of infection of Helicobacter pylori suppresses apoptosis of B lymphocytes. Cancer Res. 2006;66:6834-42.
79. Bossenmeyer-Pourié C, Kannan R, Ribieras S, et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol. 2002;157:761-70.
80. Su F, Xiao R, Chen R, et al. WIPF1 promotes gastric cancer progression by regulating PI3K/Akt signaling in a myocardin-dependent manner. iScience. 2023;26:108273.
81. Wen X, Jin HY, Li M, et al. Methylation statuses of NCOR2, PARK2, and ZSCAN12 signify densities of tumor-infiltrating lymphocytes in gastric carcinoma. Sci Rep. 2022;12:862.
